Belinda Laboratories Profile
Key Indicators
- Authorised Capital ₹ 40.00 Cr
- Paid Up Capital ₹ 39.49 Cr
- Company Age 13 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -47.24%
- Profit Growth -44.64%
- Ebitda -25.49%
- Net Worth 0.75%
- Total Assets -1.81%
About Belinda Laboratories
Belinda Laboratories Private Limited (BLPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 May 2011 and has a history of 13 years and eight months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 40.00 Cr and a paid-up capital of Rs 39.49 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Belinda Laboratories Private Limited India is Prabhdeep Singh as COMPANY SECRETARY. Bezhan Mukimi and Abdurakhmon Karimov serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33110DL2011PTC220013
- Company No.
220013
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 May 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Belinda Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Prabhdeep Singh | Company Secretary | 05-Dec-2016 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bezhan Mukimi  | Director | 01-Jun-2015 | Current |
| Abdurakhmon Karimov | Director | 03-Jun-2015 | Current |
Financial Performance of Belinda Laboratories.
Belinda Laboratories Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 47.24% decrease. The company also saw a substantial fall in profitability, with a 44.64% decrease in profit. The company's net worth moved up by a moderate rise of 0.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Belinda Laboratories?
In 2023, Belinda Laboratories had a promoter holding of 60.00% and a public holding of 40.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Belinda Private LimitedAbdurakhmon Karimov is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Belinda Laboratories?
Unlock and access historical data on people associated with Belinda Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Belinda Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Belinda Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
